Integra LifeSciences Holdings Corporation (FRA:IL3)
| Market Cap | 730.36M -56.6% |
| Revenue (ttm) | 1.40B +5.0% |
| Net Income | -422.17M |
| EPS | -5.52 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 4.80 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | 13 |
| Open | 9.10 |
| Previous Close | 9.00 |
| Day's Range | 9.10 - 9.10 |
| 52-Week Range | 9.00 - 25.40 |
| Beta | n/a |
| RSI | 29.83 |
| Earnings Date | Feb 20, 2026 |
About FRA:IL3
Integra LifeSciences Holdings Corporation manufactures and sells surgical instrument, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamp... [Read more]
News
Integra LifeSciences Holdings Corporation (IART) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
2026-01-21. The following slide deck was published by Integra LifeSciences Holdings Corporation in conjunction with this event.
HARBOR CAPITAL ADVISORS, INC. Sells 12 Shares of Integra Lifesciences Holdings Corp (IART)
HARBOR CAPITAL ADVISORS, INC. Sells 12 Shares of Integra Lifesciences Holdings Corp (IART)
3 Undervalued Medical Instrument Stocks Poised to Grow in 2026
FMS, IART and STE trade below historical valuations. Easing cost pressure and improved execution set the stage for potential upside in 2026 for these companies.
Integra Lifesciences Holdings Corp at JPMorgan Healthcare Conference Transcript
Integra Lifesciences Holdings Corp at JPMorgan Healthcare Conference Transcript
Integra LifeSciences Leadership to Present at the 44th Annual J.P. Morgan Healthcare Conference
PRINCETON, N.J., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer M...
Integra LifeSciences: Potential Only Takes You So Far Without Execution
Get the latest on Integra LifeSciences' operational challenges, market outlook, and recovery prospects.
Integra Lifesciences Holdings Corp at Citi Global Healthcare Conference Transcript
Integra Lifesciences Holdings Corp at Citi Global Healthcare Conference Transcript
Integra LifeSciences Leadership to Present at the Citi 2025 Global Healthcare Conference
PRINCETON, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that chief executive officer M...
Integra LifeSciences (IART) Welcomes CMS Inclusion of Key Products in 2026 Rules
Integra LifeSciences (IART) Welcomes CMS Inclusion of Key Products in 2026 Rules
Integra LifeSciences Welcomes Policy Advancements Supporting Medicare Beneficiary Access
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, commends the Centers for Medicare & Medicaid S...
Integra LifeSciences Receives FDA Clearance For Cardiac Use Of CUSA Clarity System
(RTTNews) - Integra LifeSciences (IART) announced that it has received U.S. FDA 510(k) clearance for its CUSA Clarity Ultrasonic Surgical Aspirator System, for use in cardiac surgery.
Integra LifeSciences (IART) Gains FDA Clearance for Cardiac Surgery Device
Integra LifeSciences (IART) Gains FDA Clearance for Cardiac Surgery Device
Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA Clarity Ultrasonic Surgical Aspirator System for Cardiac Surgeries
PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, is pleased to announce the FDA 510(k) clearanc...
Integra LifeSciences Receives FDA 510(k) Clearance for Use of the CUSA® Clarity Ultrasonic Surgical Aspirator System for Cardiac Surgeries
PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, is pleased to announce the FDA 510(k) clearanc...
Insider Buying: Jeffrey Graves Acquires Shares of Integra Lifesciences Holdings Corp (IART)
Insider Buying: Jeffrey Graves Acquires Shares of Integra Lifesciences Holdings Corp (IART)
Integra Lifesciences (IART) Sees Revised Analyst Ratings Today | IART Stock News
Integra Lifesciences (IART) Sees Revised Analyst Ratings Today | IART Stock News
Citigroup Maintains "Sell" Rating on Integra Lifesciences (IART) with Lowered Price ...
Citigroup Maintains "Sell" Rating on Integra Lifesciences (IART) with Lowered Price Target | IART Stock News
JP Morgan Raises Price Target for Integra Lifesciences (IART) to $13 | IART Stock News
JP Morgan Raises Price Target for Integra Lifesciences (IART) to $13 | IART Stock News
Integra Lifesciences Holdings Corp (IART) Q3 2025 Earnings Call Highlights: Strong EPS Growth ...
Integra Lifesciences Holdings Corp (IART) Q3 2025 Earnings Call Highlights: Strong EPS Growth Amid Supply Challenges
Q3 2025 Integra Lifesciences Holdings Corp Earnings Call Transcript
Q3 2025 Integra Lifesciences Holdings Corp Earnings Call Transcript
Integra LifeSciences (IART) Reports Strong Q3 Despite Supply Challenges
Integra LifeSciences (IART) Reports Strong Q3 Despite Supply Challenges
Integra LifeSciences Holdings Corporation (IART) Q3 2025 Earnings Call Transcript
Integra LifeSciences Holdings Corporation (IART) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDTCompany ParticipantsChristopher Ward - Senior Director of...
Integra (IART) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Integra (IART) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compa...